AcelRx Gives Patent Update - Analyst Blog
October 09 2013 - 5:05PM
Zacks
AcelRx Pharmaceuticals, Inc. (ACRX) gave an
update on its rising patent estate. The company now has 19 patents
issued globally. These patents cover AcelRx Pharma’s lead candidate
Zalviso in addition to the company’s proprietary platform
technologies through 2027 – 2031.
These 19 patents are composed of 9 U.S. patents, 3 European
patents and 7 patents issued in international territories including
Japan and China.
In 2013, 4 U.S. patents were issued – (1) patent #8,357,114
entitled "Drug dispensing device with flexible push rod" (Jan 22,
2013); (2) patent #8,499,966 entitled "Method of moving a delivery
member of a dispensing device for administration of oral
transmucosal dosage forms" (Aug 6, 2013); (3) patent #8,535,714
entitled "Small volume oral transmucosal dosage forms containing
sufentanil for treatment of pain" (Sep 17, 2013); and (4) patent
#8,548,623 entitled "Storage and dispensing devices for
administration of oral transmucosal dosage forms" (Oct 1,
2013).
In 2013, 1 European patent was issued, #EP1973593B1, entitled
"Drug storage and dispensing devices and systems comprising the
same" (Apr 10, 2013).
We note that AcelRx Pharma is seeking U.S. approval for Zalviso
for managing the moderate-to-severe acute pain in adults in the
hospital setting. The New Drug Application (NDA) was submitted by
the company to the U.S. Food and Drug Administration (FDA) for
Zalviso in the above indication last month. The NDA was submitted
on the basis of data from two phase III studies – one in patients
following major abdominal surgery and the other in patients
following major joint replacement surgery.
AcelRx Pharma carries a Zacks Rank #3 (Hold). Currently,
companies like Roche Holding (RHHBY), Isis
Pharmaceuticals, Inc. (ISIS) and Actelion
Ltd. (ALIOF) look more attractive with a Zacks Rank #1
(Strong Buy).
ACELRX PHARMACT (ACRX): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jul 2023 to Jul 2024